News

Lupin in distribution agreement with Medis for NaMuscla

The agreement enables expanded patient access to the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories

Lupin has entered into a distribution agreement with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Medis will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries. NaMuscla is the first and only licensed product for this indication.

Under the agreement, Medis will initially focus on the commercialisation of NaMuscla in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase. Lupin will continue the commercialisation of NaMuscla in Germany, France, and the UK.

“The distribution agreement represents an important milestone for Lupin as we continue the rollout of NaMuscla across Europe. We know that collaborating with partners which are highly focussed in their territories means patients receive medicines most efficiently,” said Thierry Volle,
President, EMEA, Lupin.

“At Medis, we are very excited to partner with Lupin and are further committed to using our expertise in comprehensive commercialisation to provide new, innovative treatment options like NaMuscla that address patients’ unmet needs. For us, each patient counts,” said Martina Perharič, CEO, Medis. “As a pioneer in full-service pharmaceutical distribution for the CEE region, we have gained extensive knowledge of the complex markets in the region. This allows us to launch NaMuscla quickly and effectively in selected countries and provide excellent support to our partner Lupin.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close